AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39687049
Drug: 1 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Hz rTMS to the right DLPFC and intermittent theta burst stimulation (iTBS) to the cerebellum, delivered sequentially in 20 sessions along with antipsychotics.
Trial: 39687049
Drug: Sham condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham condition along with antipsychotics.
Trial: 39687431
Drug: Oral maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral maintenance therapy with trofosfamide (2 × 75 mg/m²), etoposide, and idarubicin for 25 weeks (8 courses of 10 days each)
Trial: 39687431
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (S-arm)
Trial: 39688408
Drug: Leritrelvir 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leritrelvir 400 mg
Trial: 39689146
Drug: COACH intervention
RxNorm normalized name: coachwhip stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COACH intervention (six-month intervention including six monthly hypertension educational sessions, monthly blood pressure monitoring, follow up care coordination, fully subsidized antihypertensive medications, standardized treatment algorithm, training for providers)
Trial: 39689944
Drug: Electrically heated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrically heated mittens worn for at least 15 minutes daily for six weeks
Trial: 39689944
Drug: Control mittens
RxNorm normalized name: praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control mittens (heating elements disconnected) worn for at least 15 minutes daily for six weeks
Trial: 39690158
Drug: Rezvilutamide plus
RxNorm normalized name: Rezvilutamide
DrugBank: Rezvilutamide (DB19133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezvilutamide plus androgen deprivation therapy (REZ-ADT)
Trial: 39691173
Drug: Various intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various intra-articular injections, oral opioid and nonopioid medications (including nonsteroidal anti-inflammatory drugs), cryo nerve blocks, radiofrequency ablations, novel treatment modalities, other physical therapy modalities (including muscle strengthening), and total knee arthroplasties.
Trial: 39691173
Drug: Index joint-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Index joint-directed treatments
Trial: 39691584
Drug: SMS reminders
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS reminders for treatment adherence and ART refill visits
Trial: 39691747
Drug: Kinesiotaping plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesiotaping plus standard analgesic treatment
Trial: 39691834
Drug: Artificial Intelligence
RxNorm normalized name: Intelence
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artificial Intelligence of Medicine (AIMED) system using convolutional neural networks and MobileNetV3-large
Trial: 39692004
Drug: Pembrolizumab 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 4 mg/kg (maximum 400 mg), single cycle
Trial: 39692004
Drug: Surgery after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery after pembrolizumab treatment
Trial: 39692262
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT)-based mobile application
Trial: 39692276
Drug: Aerobic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic and resistance exercises with physiotherapist in primary care twice a week for 12 weeks and daily walks
Trial: 39692276
Drug: Unsupervised home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised home-based exercise including daily walks
Trial: 39692552
Drug: Early aerobic
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early aerobic exercise treatment
Trial: 39693081
Drug: Brexpiprazole +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole + Sertraline
Trial: 39693081
Drug: Sertraline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline + Placebo
Trial: 39693096
Drug: Potassium nitrate
RxNorm normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium nitrate (KNO3) (6 mmol 3 times daily)
Trial: 39693227
Drug: Mirikizumab 300
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirikizumab 300 mg for weight >40 kg, 5 mg/kg for weight ≤40 kg every 4 weeks during induction; subcutaneous mirikizumab 200 mg (>40 kg), 100 mg (>20 to ≤40 kg), or 50 mg (≤20 kg) every 4 weeks during maintenance therapy.
Trial: 39693244
Drug: Antagonists blocking
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antagonists blocking TRPA1, TRPM8, NaV1.7, and NaV1.8
Trial: 39693245
Drug: Antiretroviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment (ART) for 6 months
Trial: 39693261
Drug: Earlier physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Earlier physical therapy (started within 1 week)
Trial: 39693261
Drug: Later physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Later physical therapy (started after 6 weeks)
Trial: 39693261
Drug: Earlier physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Earlier physical therapy
Trial: 39693261
Drug: Later physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Later physical therapy
Trial: 39693517
Drug: ATRA/chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATRA/chemotherapy
Trial: 39693517
Drug: oral-AAA (ATRA/oral-ATO/ascorbic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral-AAA (ATRA/oral-ATO/ascorbic acid with ATO maintenance)
Trial: 39693517
Drug: ATRA/chemotherapy/non-ATO maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATRA/chemotherapy/non-ATO maintenance
Trial: 39693517
Drug: ATRA/chemotherapy/ATO maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATRA/chemotherapy/ATO maintenance
Trial: 39693517
Drug: oral-AAA
RxNorm normalized name: Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral-AAA
Trial: 39694102
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high individual and low neighborhood SES
Trial: 39694205
Drug: Budesonide orodispersible
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide orodispersible tablets (BOT) 0.5 or 1.0 mg, twice daily
Trial: 39694207
Drug: Efmarodocokin alfa
RxNorm normalized name: Efmarodocokin alfa
DrugBank: Efmarodocokin alfa (DB16398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efmarodocokin alfa 30 μg/kg
Trial: 39694207
Drug: Efmarodocokin alfa
RxNorm normalized name: Efmarodocokin alfa
DrugBank: Efmarodocokin alfa (DB16398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efmarodocokin alfa 60 μg/kg
Trial: 39694207
Drug: Efmarodocokin alfa
RxNorm normalized name: Efmarodocokin alfa
DrugBank: Efmarodocokin alfa (DB16398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efmarodocokin alfa 90 μg/kg
Trial: 39694978
Drug: Functional Assessment
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Assessment of Cancer Therapy item GP5 (GP5)
Trial: 39695117
Drug: gecacitinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gecacitinib (100 mg BID)
Trial: 39695117
Drug: hydroxyurea (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydroxyurea (500 mg BID)
Trial: 39695323
Drug: Psilocybin (0215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (0215 mg/kg body weight)
Trial: 39695436
Drug: Monthly phone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly phone calls assessing fall status, healthcare utilization, physical activity, and exercise self-efficacy
Trial: 39695436
Drug: Exercises focusing
RxNorm normalized name: ficusin
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercises focusing on strength, balance, coordination, flexibility, and aerobic endurance; weekly educational sessions on falls risk
Trial: 39695508
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of distance and near phoria with positive fusional vergence tests
Trial: 39695586
Drug: Pharmacist-led interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led interventions including medication reconciliation and medication reviews at admission and discharge
Trial: 39695599
Drug: PGY-3 emergency
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGY-3 emergency medicine residents
Trial: 39695675
Drug: Chemotherapy (CHT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CHT) with radiotherapy (RT) including proton and carbon ion RT (CIRT) and stereotactic body radiation therapy (SBRT) with a minimum dose of 40 Gy, conventional fractionation with concomitant fluoropyrimidine-with/without oxaliplatin-based CHT (CRT) in neoadjuvant setting.
Trial: 39695675
Drug: CIRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIRT with a dose of 40-60 Gy relative biological effectiveness (RBE) administered with a daily dose fraction ranging between 3 and 4.8 Gy RBE.
Trial: 39695728
Drug: Artesunate (AS)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate (AS) monotherapy for 7 days
Trial: 39696004
Drug: RSM01 monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSM01 monoclonal antibody
Trial: 39696092
Drug: Long-acting G-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting G-CSF
Trial: 39696092
Drug: Short-acting G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting G-CSF
Trial: 39696103
Drug: FACT-G and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FACT-G and EQ-5L-5D
Trial: 39696255
Drug: Not-daily coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not-daily coffee consumption
Trial: 39696526
Drug: Asciminib 40
RxNorm normalized name: asciminib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asciminib 40 mg QD add-on to imatinib 400 mg QD
Trial: 39696526
Drug: Asciminib 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asciminib 60 mg QD add-on to imatinib 400 mg QD
Trial: 39696526
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg QD continued therapy
Trial: 39696609
Drug: Facilitated access
RxNorm normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Facilitated access to oral PrEP
Trial: 39696680
Drug: Amulirafusp alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amulirafusp alfa (IMM0306) at doses of 40-2000 μg/kg
Trial: 39696680
Drug: Amulirafusp alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amulirafusp alfa (IMM0306) at doses of 800-2000 μg/kg
Trial: 39697201
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of PEG-IFN-
Trial: 39697396
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) adjunctive to quetiapine
Trial: 39697620
Drug: Dalpiciclib plus
RxNorm normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib plus endocrine therapy (ET)
Trial: 39697813
Drug: Text message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text message reminder intervention for self-management of oral anticancer medication
Trial: 39697819
Drug: Mindful Awareness
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindful Awareness in Body-oriented Therapy (MABT) as an adjunct to medication for opioid use disorder (MOUD)
Trial: 39697819
Drug: Medication for
RxNorm normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication for opioid use disorder (MOUD) only
Trial: 39697865
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec for 3 months
Trial: 39698150
Drug: 10 L/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 L/min supplemental oxygen (high-dose oxygen therapy)
Trial: 39699595
Drug: Maternal thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal thiamine supplementation (0, 1.2, 2.4, or 10 mg daily)
Trial: 39699848
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin icodec with dosing guide app
Trial: 39700102
Drug: INTERACT3 Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INTERACT3 Care Bundle including protocols for management of physiological variables such as systolic blood pressure (SBP) reduction (target <140mmHg), glucose control (target 6.1-7.8 mmol/L for non-diabetics and 7.8-10.0 mmol/L for diabetics), anti-pyrexia treatment (target body temperature ≤37.5°C), and rapid reversal of warfarin-related anticoagulation (target INR <1.5).
Trial: 39700448
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of direct oral anticoagulants (DOACs) within 48 hours for minor and moderate stroke, 6-7 days for major stroke.
Trial: 39700448
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of direct oral anticoagulants (DOACs) after 48 hours for minor, 3-4 days for moderate, 12-14 days for major stroke.
Trial: 39700502
Drug: Danicopan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danicopan (150 mg 3 times daily)
Trial: 39700681
Drug: Nivolumab (Nivo)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (Nivo) as early switch maintenance after 1st-line chemotherapy, administered at a dose of 240 mg i.v. every 2 weeks until progressive disease, intolerable toxicity, or for a maximum of 2 years.
Trial: 39700737
Drug: Tablet-based multimodal
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based multimodal training (n = 16)
Trial: 39701583
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control group (maintains normal daily activities, offered intervention within 6 months from ASCT).
Trial: 39702045
Drug: HAZDPac treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAZDPac treatment (Hydroxychloroquine paired with Azithromycin, Vitamin C, Vitamin D, and Zinc)
Trial: 39702102
Drug: Secondary outcomes:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary outcomes: daily step count via wearable sensors
Trial: 39702118
Drug: Weekly piano
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly piano practice (PP)
Trial: 39702151
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 10 mg (3 doses: pre-anesthesia, 24h, and 48h post-surgery)
Trial: 39702343
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment during physiotherapy
Trial: 39702395
Drug: HEV239 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEV239 vaccine (two doses)
Trial: 39702395
Drug: HEV239 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEV239 vaccine (single dose)
Trial: 39702402
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 1000 mg vancomycin suspended in 25 mL of normal saline after arthrotomy closure
Trial: 39702402
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 1000 mg vancomycin
Trial: 39702504
Drug: Process-based therapy
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Process-based therapy (PBT)
Trial: 39702504
Drug: Routine cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine cognitive behavioral therapy (r-CBT)
Trial: 39702896
Drug: AS03-adjuvanted H7N9
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted H7N9 vaccine (1.9 μg, 3.75 μg, and 7.5 μg)
Trial: 39702896
Drug: AS03-adjuvanted H7N9
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted H7N9 vaccine (various doses)
Trial: 39702896
Drug: AS03-adjuvanted H7N9
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted H7N9 vaccine
Trial: 39703191
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical nerve stimulation (TENS) of the greater occipital nerves (GON) for 8-12 weeks, stimulating for 30 minutes twice daily
Trial: 39703564
Drug: Tailored dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored dose-dense epirubicin/cyclophosphamide (EC) and docetaxel (D)
Trial: 39705540
Drug: Voruciclib (initially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voruciclib (initially 100 mg daily continuously on a 28-day cycle, then changed to days 1-14 of a 28-day cycle); dose escalation stopped at 200 mg.
Trial: 39705540
Drug: Voruciclib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voruciclib (200 mg on days 1-14 of a 28-day cycle);
Trial: 39706212
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of 2×10^6 allogeneic umbilical cord-derived mesenchymal stromal cells
Trial: 39706209
Drug: Guselkumab 200
RxNorm normalized name: guselkumab 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 200 mg given intravenously at weeks 0, 4, and 8 (induction)
Trial: 39706209
Drug: Guselkumab 200
RxNorm normalized name: guselkumab 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 200 mg given subcutaneously every 4 weeks (maintenance)
Trial: 39706209
Drug: Guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 100 mg given subcutaneously every 8 weeks (maintenance)
Trial: 39706632
Drug: NG101 (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG101 (45 mg intrathecal injections, 6 doses every 5 days over 4 weeks)
Trial: 39706761
Drug: Ledipasvir/Sofosbuvir (LDV/SOF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir/Sofosbuvir (LDV/SOF) fixed dosing (45/200 mg)
Trial: 39706803
Drug: Medication monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication monitoring (control group)
Trial: 39707077
Drug: Risankizumab 1800
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Risankizumab 1800 mg intravenous infusion once every 4 weeks for four doses
Trial: 39707126
Drug: Pre-treatment contrast-enhanced
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment contrast-enhanced CT (CECT)
Trial: 39707137
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy (SMT), administered once every other day for 30 min per session, totaling 14 sessions over 4 weeks
Trial: 39707137
Drug: Healthy controls
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy controls (HCs), no SMT treatment
Trial: 39707138
Drug: Juan Bi
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juan Bi Pill (JBP) combined with Methotrexate (MTX, 10 mg per week)
Trial: 39707138
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with Methotrexate (MTX, 10 mg per week)
Trial: 39707209
Drug: Liberal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal oxygen therapy (target SpO2 of ≥ 96%)